Petros Pharmaceuticals, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
PTPI Nasdaq 3840 www.petrospharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Nov 16th, 2024 1:08 pm
Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - Sep 11th, 2024 1:15 pm
Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 1:00 pm
Petros Pharmaceuticals Second Quarter 2024 Earnings: Beats Expectations - Aug 17th, 2024 1:56 pm
Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil) - Jul 29th, 2024 1:20 pm
Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance - Jul 16th, 2024 1:00 pm
Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch - May 29th, 2024 1:00 pm
Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA - May 21st, 2024 1:15 pm
Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe - May 14th, 2024 1:15 pm
Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals - May 14th, 2024 11:00 am
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health - Apr 23rd, 2024 1:15 pm
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil) - Apr 16th, 2024 1:15 pm
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status - Apr 2nd, 2024 1:15 pm
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider - Mar 19th, 2024 1:00 pm
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider - Feb 14th, 2024 2:15 pm
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch - Jan 24th, 2024 2:15 pm
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch - Jan 17th, 2024 2:00 pm
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status - Dec 12th, 2023 3:00 pm
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider - Dec 12th, 2023 2:15 pm